On Mar. 12, 2020, Chembio Diagnostics announced it has entered into a worldwide strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus and IgM and IgG antibodies on both the LumiraDx and Chembio DPP platforms.